BAYRY
Same seat, fancier sunglasses
Deutsche Bank isn’t exactly swinging from the rafters here. It kept Bayer at Neutral, which is analyst-speak for “we’re not impressed enough to chase it, but we’re not running for the exits either.”
The part investors will actually notice
The bigger headline is the price target hike — from €23 to €43. That’s a chunky upgrade in what the bank thinks Bayer could be worth, and in market land that kind of re-rating can matter more than the rating label itself. Same restaurant, better Yelp score.
Why this matters
For you, the takeaway is simple: Deutsche Bank is signaling that its outlook on Bayer has improved materially, even if it’s still not ready to call the stock a slam dunk. That can help sentiment, especially when a stock has been living under the shadow of legal baggage and a generally skeptical analyst crowd.
Big picture
This is the classic Wall Street compromise: “We see better value, but we’re keeping one foot near the door.” If Bayer keeps stacking up positive catalysts, today’s Neutral could start looking a lot less lukewarm.